Cerebral infarction treatment medical insurance can not be fully reimbursed.
In January 2016, the Beijing Municipal Bureau of Human Resources and Social Security issued the "Trial Measures for Single-Patient Payment for Ischemic Stroke Intervention in Beijing Basic Medical Insurance", which formally incorporates single-patient payment for acute cerebral infarction intervention into the city's basic medical insurance. It applies to patients suffering from ischemic stroke who have undergone percutaneous cerebrovascular stent implantation, percutaneous cerebrovascular balloon angioplasty, and percutaneous cerebrovascular thrombolysis.
Starting from April 1, 2016, patients receiving acute cerebral infarction interventional treatment at Rocket Force General Hospital can be reimbursed by medical insurance. The patient's out-of-pocket percentage in the cost of the above treatment program is 8%; for expensive medical consumables with a single cost of 500 yuan or more, the out-of-pocket percentage is 30%.
Taking the intracranial stenting surgery for acute cerebral infarction carried out by the hospital as an example, the total cost averaged around 90,000 yuan, and after the implementation of medical insurance reimbursement, the insured patients would only need to spend between 20,000 and 30,000 yuan.
Expanded Information
In 2016, the domestic key cities in public hospitals antithrombotic drugs TOP5 clopidogrel, low molecular heparin, rivaroxaban, aspirin, bezprevirin medication amounted to 2.75 billion yuan, occupying 80% of the public hospital antithrombotic drugs market.
Currently the more clinically used drugs are clopidogrel and aspirin. The entry of these drugs into the medical insurance catalog is of some epoch-making significance. It is a boon for those who are ineffective or intolerant with conventional anticoagulants.
The 2017 new version of the National Health Insurance Catalog*** includes 31 antithrombotic drugs, and eight newly added antithrombotic drugs: direct factor Xa inhibitors, including apixaban oral ever-release, sulfadoxine heparan decanoate sodium injection, sulodexide oral ever-release;
direct thrombin inhibitors, including dabigatran etexilate oral ever-release, argatroban injection. Platelet coagulation inhibitors, including tegretol oral sustained-release, indobufen oral sustained-release, and eptifibatide injection.
People's Daily Online - Beijing's Acute Cerebral Infarction Intervention Treatment Pilot Reimbursement
People's Daily Online - Eight New Anti-Thrombotic Drugs Into Medical Insurance